Loading company…
Riskpilot
← Back to search
Sign in
Get full access
VEAKROSSEN APOTEK AS
AS
Active
Org 930243035
Bleikmyrvegen 2A, 4276 Veavågen
Retail sale of pharmaceutical products · NACE 4773
Est. 2022
7 employees
Watchlist
Share
Overview
Financials
People & ownership
Related companies
Revenue 2024
NOK 19,8M
+17% vs 2023
EBITDA margin
5.4%
+1314% vs 2023
Equity ratio
6.1%
Financial strength
Net profit 2024
NOK 861K
+1362% vs 2023
EBITDA — year on year
NOK millions
1M
1M
1M
0M
0M
0M
2022
0M
0%
2023
1M
+100%
2024
Key figures
Annual report 2024
Revenue
NOK 19,8M
+17%
EBITDA
NOK 1,1M
+1314%
Net profit
NOK 861K
+1362%
Total assets
NOK 18,1M
-7%
Equity
NOK 1,1M
+354%
Employees
7
—
Company information
Legal name
VEAKROSSEN APOTEK AS
Org number
930243035
Legal form
Aksjeselskap
NACE code
4773 · Retail sale of pharmaceutical products
Founded
16. november 2022
Share capital
NOK 30 000
Employees
7 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styret i fellesskap.
Company purpose
Drift av apotekvirksomhet.
Contact
Address
Bleikmyrvegen 2A, 4276 Veavågen
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Retail sale of pharmaceutical products
Companies in Karmøy
All Norway companies
Revenue
NOK millions
0M
6M
12M
17M
23M
2M
2022
17M
2023
20M
2024
EBITDA
NOK millions
0M
0M
1M
1M
1M
0M
2022
0M
2023
1M
2024
Income statement
NOK thousands
Item
2022
2023
2024
Revenue
2 160
16 948
19 781
Staff expenses
−258
−3 166
−2 439
EBITDA
166
75
1 059
Depreciation & amort.
−2
−19
−19
EBIT
165
56
1 040
Net financials
0
20
64
Profit before tax
165
76
1 104
Tax
35
17
243
Net profit
130
59
861
Balance sheet
NOK thousands
Item
2022
2023
2024
Total assets
4 018
19 370
18 072
Equity
185
244
1 105
Long-term debt
507
14 509
14 010
Short-term debt
3 326
4 617
2 958
Total debt
3 834
19 126
16 967
Financial ratios
5-year trend
EBITDA margin
5.4%
This company
15.8%
Market median
-66% vs market
2022
2024
Equity ratio
6.1%
This company
38.2%
Market median
-84% vs market
2022
2024
Return on equity
78.0%
This company
18.4%
Market median
+324% vs market
2022
2024
Net profit margin
4.4%
This company
8.1%
Market median
-46% vs market
2022
2024
Asset turnover
1.09×
This company
1.12×
Market median
+3% vs market
2022
2024
Debt / equity
15.35×
This company
0.62×
Market median
-2376% vs market
2022
2024
Annual reports & filings
Annual report 2024
Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Brønnøysundsregistrene · Period 2022-08-31 – 2022-12-31
View
PDF
Management
Actively employed in the business
No data on file.
Board of directors
Non-executive oversight
Name
Role
Member since
Current (2)
LK
Linn Karin Amiri Oksebåsen
Chairman
2022
FC
Fabian Chia Amiri
Board of Directors
2022
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Apoproffs Sverige Ab
Company
51%
51%
2024
Avicenna Invest As
Company
49%
49%
2024
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
No registered parent or subsidiaries
Board network connections
Board members of VEAKROSSEN APOTEK AS also hold positions in
0
other companies.
Person
Role here
Other companies
Linn Karin Amiri Oksebåsen
Chairman
0 companies
Fabian Chia Amiri
Board of Directors
0 companies